31 – 45 of 103
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2019
-
Mark
Is Data Sharing Caring Enough About Patient Privacy?: Part I: The Background
2019)(
- Other contribution › Miscellaneous
-
Mark
What lurks in the shadows of the openness hyperbole for biopharmaceuticals?
2019) In Drug Development Research(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Mayo’s impact on patent applications related to biotechnology, diagnostics and personalized medicine
(
- Contribution to journal › Article
-
Mark
An Update on Research- & Bolar exemptions in the U.S. and Europe: Unsolved questions and new developments in an increasingly important area of law
(
- Contribution to journal › Article
-
Mark
Global Genes, Local Concerns: Legal, Ethical and Scientific Challenges in International Biobanking
2019)(
- Book/Report › Book
-
Mark
Much ado about something. Legal, ethical, and scientific challenges in international biobanking and translational exploitation
2019) 1.(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
Shadow health records meet new data privacy laws
(
- Contribution to journal › Article
-
Mark
An "export-only" exception to pharmaceutical patents in Europe: Should the U.S. follow suit?
(
- Contribution to journal › Article
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part 2)
2019)(
- Other contribution › Miscellaneous
-
Mark
How does emerging patent case law in the US and Europe affect precision medicine?
(
- Contribution to journal › Article
-
Mark
Nudges or Shoves in the Secondary Use of Health Data: What is the More Desirable Approach? (Part I)
2019)(
- Other contribution › Miscellaneous
- 2018
-
Mark
Big Data and intellectual property rights in the health and life sciences
2018) p.311-323(
- Chapter in Book/Report/Conference proceeding › Book chapter
-
Mark
A Ray of Light in Muddy Waters? -The CJEU rules on combination SPCs in C-121/17 Teva v Gilead
(
- Contribution to journal › Article
-
Mark
How much is too much?- Defining the Metes and Bounds of Excessive Pricing in the Pharmaceutical Sector
(
- Contribution to journal › Article
-
Mark
Challenges for the sustainability of university-run biobanks
(
- Contribution to journal › Article